BDX logo

BDX

Becton Dickinson and Company

$201.91
-$1.57(-0.77%)
76
Overall
95
Value
91
Tech
44
Quality
Market Cap
$53.26B
Volume
1.95M
52W Range
$162.29 - $251.99
Target Price
$205.40

Company Overview

Mkt Cap$53.26BPrice$201.91
Volume1.95MChange-0.77%
P/E Ratio31.7Open$203.00
Revenue$21.8BPrev Close$203.48
Net Income$1.7B52W Range$162.29 - $251.99
Div Yield4.20%Target$205.40
Overall76Value95
Quality44Technical91

No chart data available

About Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

Becton Dickinson adopts executive severance plan, equity increase

Becton Dickinson ( ($BDX) ) just unveiled an update. On January 27, 2026, BD’s board adopted a new Executive Severance Plan that standardizes sever...

TipRanks Auto-Generated Newsdesk4 days ago

Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), Regeneron (REGN)

Howard Kim13 days ago

Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up

TipRanks Weekend Auto-Generated Newsdesk17 days ago

BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors

TipRanks Clinical-Trials-Auto-Generated Newsdesk18 days ago

Abingdon Health lifts H1 revenues 45% and backs full-year guidance amid US expansion

TipRanks UK Auto-Generated Newsdesk19 days ago
ABCD
1SymbolPriceChangeVol
2BDX$201.91-0.8%1.95M
3
4
5
6

Get Becton Dickinson and Company Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.